CD58 and cancer: Heatmap analysis demonstrated widespread correlations between CD58 and these immunomodulators in nearly all cancers, except for CHOL, ESCA, diffuse large B-cell lymphoma (DLBC), and uterine carcinosarcoma (UCS) (Figures 2A–E).